At a glance
- Originator Shire Pharmaceuticals Group
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 18 May 1995 Discontinued-Preclinical for Cancer in Canada (Unknown route)